# Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

> **NCT07098806** · PHASE1 · RECRUITING · sponsor: **Plus Therapeutics** · enrollment: 24 (estimated)

## Conditions studied

- Leptomeningeal Metastasis

## Interventions

- **DRUG:** 186RNL

## Key facts

- **NCT ID:** NCT07098806
- **Lead sponsor:** Plus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-02
- **Primary completion:** 2026-10-02
- **Final completion:** 2031-10-02
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07098806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07098806, "Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07098806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*